Adding metformin to letrozole and abemaciclib (Verzenio) was tied to deep responses and prolonged progression-free survival ...

New agents targeting endocrine therapy and CDK4/6 resistance in hormone receptor–positive breast cancer are in development.

A couple presents after 1 year without conception despite having had sexual intercourse 2 or 3 times per week. The 36-year-old female partner has menses (lasting 3 to 5 days) every 26 to 30 days.

ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...

Although still having a negative effect on cognition, data from the Breast International Group (BIG) 1–98 trial suggest that letrozole use ... After 2 years, 151 women were available for ...

while Roche's phase 2 acelERA trial recruited post-menopausal and pre/perimenopausal females, as well as males. Sanofi's phase 3 AMEERA-5 study compared the drug to letrozole – both given on top ...

In AZ's fourth-quarter results conference, chief executive Pascal Soriot reiterated the company's view that camizestrant has the potential to become a $5 billion ... and CAMBRIA-2 studies, as ...

People without diabetes can lose up to 13% of their starting weight in 6 months using tirzepatide (Mounjaro) as an off-label ...

Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to ...

Roche (RHHBY) is looking to boost its presence in the booming weight-loss market through an exclusive collaboration and ...

Ruxolitinib cream 1.5% shows “breakthrough” results as a treatment for prurigo nodularis, according to a presenter at the ...